Inside Dallas Renal Group's AI rollout: Lessons from scaling agentic patient access across a multi-site nephrology network

​Every unanswered call in a nephrology practice represents more than a scheduling issue. It compounds into delayed lab follow-ups, missed dialysis coordination, weakened chronic care adherence, and revenue leakage that pressures already thin margins.

​As nephrology groups test AI across patient access, scheduling, and revenue operations, two realities are emerging. Practices that delay risk falling behind as competitors scale patient panels without scaling headcount. And even early adopters are encountering a gap between AI promises and operational outcomes. Without the right alignment across technology, workflows, and clinical teams, pilots stall.

​This conversation goes inside one of the largest nephrology networks in Texas to examine what the rollout actually looked like, where it created leverage, and what other nephrology leaders should know before they start.

• How Dallas Renal Group structured its agentic AI patient access rollout around nephrology-specific workflows, including scheduling, lab coordination, dialysis follow-ups, and multi-location routing, rather than generic call automation
• ​Where the operational leverage actually showed up: missed call recovery, peak-hour congestion, staff burnout from constant phone interruptions, and chronic care adherence
• What separated the workflows AI completed end-to-end from the ones that just created more handoffs
• ​How to evaluate AI vendors when you are running a multi-site specialty group, and the implementation missteps that quietly kill ROI
• ​Practical guidance for nephrology leaders, COOs, and practice administrators on structuring a rollout that actually delivers, from eliminating missed calls and reducing no-shows to strengthening patient access across multi-site operations

​Srinivas Danda, Chief Operating Officer, Dallas Renal Group. Leads operations across 51 clinic locations serving 45,000+ chronic kidney disease and dialysis patients, with direct accountability for the AI patient access transformation covered in this conversation.

​Kinjel Shastri, DO, Nephrologist, Michigan Kidney Consultants. A practicing nephrologist at Michigan's largest board-certified nephrology group, with 40 providers across 16 locations, and a 2025 RPA Leadership Development Program Fellow (learn more here).

​Vichar Shroff, Chief Product Officer, Confido Health Building the AI agents and voice infrastructure designed to free up clinical staff to focus on patient care.

​Tim Fitzpatrick is a founder and writer focused on advancing kidney and cardio-metabolic health. He founded Signals Group, a media and strategic advisory firm with a flagship newsletter read by over 20,000 clinicians, policy makers, advocates and industry leaders in 60 countries. Signals explores the ideas, innovations, and investments shaping kidney care, from digital health and devices to policy and payments.

​This webinar is co-hosted by Signals Group and Confido Health. Registration is reviewed before approval.